OBJECTIVES: To examine the use of buprenorphine for the treatment of opioid withdrawal (OW) in an emergency department (ED) setting. METHODS: The medical records of all adult patients who presented to the study ED during a 10 week period for OW were abstracted. Subjects were categorized as receiving buprenorphine, symptomatic treatment or no pharmacologic treatment for their OW. The three groups were compared by patient and service characteristics, withdrawal symptoms and outcomes. RESULTS: Of the 11,019 patients who presented to the ED during the 10 week study period, 158 (1.4%) were eligible. Subjects were more likely to receive buprenorphine (56%) compared to symptomatic treatment only (26%) or no pharmacologic treatment (18%). Subjects who received buprenorphine were more likely to have a history of suicide ideation (34% versus 12% p<0.05) compared to subjects who received symptomatic treatment(s) and were less likely to present with a gastrointestinal complaint (9% versus 25% p<0.05). Subjects who received buprenorphine were less likely to return to the same ED within 30 days for a drug-related visit (8%) compared to those who received symptomatic treatment (17%) (p<0.05). CONCLUSIONS: Buprenorphine was a common treatment for OW in this ED without any documented adverse outcomes. Given that it did not result in an increase in drug-related return ED visits and its proven efficacy in other settings, a prospective evaluation of its potential value to ED patients who present with OW is warranted.
OBJECTIVES: To examine the use of buprenorphine for the treatment of opioid withdrawal (OW) in an emergency department (ED) setting. METHODS: The medical records of all adult patients who presented to the study ED during a 10 week period for OW were abstracted. Subjects were categorized as receiving buprenorphine, symptomatic treatment or no pharmacologic treatment for their OW. The three groups were compared by patient and service characteristics, withdrawal symptoms and outcomes. RESULTS: Of the 11,019 patients who presented to the ED during the 10 week study period, 158 (1.4%) were eligible. Subjects were more likely to receive buprenorphine (56%) compared to symptomatic treatment only (26%) or no pharmacologic treatment (18%). Subjects who received buprenorphine were more likely to have a history of suicide ideation (34% versus 12% p<0.05) compared to subjects who received symptomatic treatment(s) and were less likely to present with a gastrointestinal complaint (9% versus 25% p<0.05). Subjects who received buprenorphine were less likely to return to the same ED within 30 days for a drug-related visit (8%) compared to those who received symptomatic treatment (17%) (p<0.05). CONCLUSIONS:Buprenorphine was a common treatment for OW in this ED without any documented adverse outcomes. Given that it did not result in an increase in drug-related return ED visits and its proven efficacy in other settings, a prospective evaluation of its potential value to ED patients who present with OW is warranted.
Authors: Dennis P Watson; Krista Brucker; Alan McGuire; Nyssa L Snow-Hill; Huiping Xu; Alex Cohen; Mark Campbell; Lisa Robison; Emily Sightes; Rebecca Buhner; Daniel O'Donnell; Jeffrey A Kline Journal: J Subst Abuse Treat Date: 2019-06-06
Authors: Elizabeth A Samuels; Gail D'Onofrio; Kristen Huntley; Scott Levin; Jeremiah D Schuur; Gavin Bart; Kathryn Hawk; Betty Tai; Cynthia I Campbell; Arjun K Venkatesh Journal: Ann Emerg Med Date: 2018-10-11 Impact factor: 5.721
Authors: Gail D'Onofrio; Patrick G O'Connor; Michael V Pantalon; Marek C Chawarski; Susan H Busch; Patricia H Owens; Steven L Bernstein; David A Fiellin Journal: JAMA Date: 2015-04-28 Impact factor: 56.272
Authors: Dennis P Watson; Tess Weathers; Alan McGuire; Alex Cohen; Philip Huynh; Clay Bowes; Daniel O'Donnell; Krista Brucker; Sumedha Gupta Journal: Drug Alcohol Depend Date: 2021-02-15 Impact factor: 4.492